Adult hepatocellular carcinoma
Therapeutic area
Oncology
Rare disease
Yes
- Definition
- Adult hepatocellular carcinoma is the most common primary liver cancer of adulthood. Derived from well-differentiated hepatocytes, it often develops from chronic liver cirrhosis which is most often due to hepatitis B and C virus or alcohol abuse. Symptoms are hepatic mass, abdominal pain and, in advanced stages, jaundice, cachexia and liver failure.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Adult hepatocellular carcinoma
- Therapeutic area
- Oncology
- adult hepatocellular carcinoma
- hepatocellular cancer
- adult HCC
- adult hepatocellular carcinoma
- adult hepatoma
- adult primary carcinoma of liver cell
- adult primary carcinoma of the liver cell
- adult primary hepatocellular carcinoma
- adult primary hepatoma
- adult primary liver cell carcinoma
- hepatocellular carcinoma of adults
- Severity
- Terminal
- Endocrinology
- Gastroenterology
- Oncology
- MONDO ID
- MONDO:0016216
- Parent condition
- MONDO:0007256
Related records
Broader conditions (26)
- Adenocarcinoma
- Cancer
- Cancer or benign tumor
- Carcinoma
- Carcinoma of liver and intrahepatic biliary tract
- Digestive system cancer
- Digestive system carcinoma
- Digestive system disorder
- Digestive system neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Endocrine gland neoplasm
- Endocrine system disorder
- Epithelial neoplasm
- Glandular cell neoplasm
- Hepatobiliary disorder
- Hepatobiliary neoplasm
- Hepatocellular carcinoma
- Human disease
Trials (165)
- 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- 3-Tesla MRI Response to TACE in HCC (Liver Cancer)
- A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
- A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
- A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene
- A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma
- A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma
- A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
- A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin
- A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion
- A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC
- A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
- A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer
- A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
- A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer
- A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer
- A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
- A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation
Drugs in development (22)
- Belinostat Phase 1
- Bevacizumab Phase 2
- Capecitabine Phase 3
- Cediranib maleate Phase 2
- Cixutumumab Phase 2
- Dasatinib anhydrous Phase 2
- Doxorubicin Phase 3
- Doxorubicin hydrochloride Phase 3
- Erlotinib hydrochloride Phase 2
- Gefitinib Phase 2
- Ixabepilone Phase 2
- Lapatinib ditosylate Phase 2
- MK-2206 Phase 2
- Oxaliplatin Phase 3
- Selumetinib Phase 2
- Sorafenib Phase 3
- Sorafenib tosylate Phase 3
- Sunitinib malate Phase 2
- Tegafur Phase 2
- Temsirolimus Phase 2